sales@jinjingroup.com

  News Introduction

Phenylpiracetam(cas 77472-70-9) for the treatment of Alzheimer's Disease

Date : 2016/9/24 10:53:13

Nootropics are brain metabolic activators (methysulfonylergotoxine mixtures such as dihydroergotoxine, nicergoline, etc.) and pyrrolidone derivatives (phenylpiracetam(cas 77472-70-9), piracetam, aniracetam, nefiracetam). Ergot alkaloids increase brain cell oxygen uptake and glucose by enhancing the metabolism of brain cells, and neurotrophic cells promote neurotransmitters, thus improving cognitive function. Pyrrolidone derivatives can increase brain metabolism, the main mechanism of action is in the neurotransmission of presynaptic membrane ion channel. By enhancing the nerve cells of the potential-dependent calcium channel current, enhanced calcium intake, thereby promoting the release of neurotransmitters. The guidelines do not recommend routine use of these drugs, but the guidelines also point out that, because of its effectiveness and safety is uncertain, clinicians often used in selected patients or adjuvant therapy.

International guidelines of phenylpiracetam(cas 77472-70-9) for the treatment of Alzheimer's Disease(AD):

International more recent authoritative guideline:
EFNS guidelines for the diagnosis and management of Alzheimer's Disease, European Journal of Neurology, 2010;
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians, Annals of Internal Medicine, 2008;

Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias, American Journal of Psychiatry, 2007.

Should explain the treatment with phenylpiracetam (cas 77472-70-9), as to ensure the benefit of long-term treatment. The current clinical problem is that the doctor is not with the patients and their families to explore the benefits of patients limited to delay the development of the disease or mild improvement, can not completely reverse or cure the disease, resulting in many patients 2 to 3 months after treatment because they do not feel the treatment effect and withdrawal, resulting in progressive disease.